

Supplementary Figure Legends

Figure S1. PFS of ALK-positive patients treated with pemetrexed-based chemotherapy. A. Comparison of ALK-positive patients treated with carboplatin/pemetrexed vs cisplatin/pemetrexed regimens. B. Comparison of ALK-positive patients treated with platinum/pemetrexed chemotherapy with and without bevacizumab.

Figure S2. PFS of younger (≤ 65 yo) ALK-positive and ALK-negative patients treated with pemetrexed-based chemotherapy. A. PFS on platinum/pemetrexed combinations given as first-line therapy or beyond. B. PFS on any nonplatinum/pemetrexed combinations or single agent pemetrexed.

Shaw et al., Supplementary Fig S1



